Wedbush Research Analysts Cut Earnings Estimates for STOK

Stoke Therapeutics, Inc. (NASDAQ:STOK - Free Report) - Research analysts at Wedbush dropped their Q1 2025 earnings per share (EPS) estimates for shares of Stoke Therapeutics in a research note issued to investors on Wednesday, February 19th. Wedbush analyst L. Chico now expects that the company will post earnings per share of ($0.58) for the quarter, down from their prior forecast of ($0.56). The consensus estimate for Stoke Therapeutics' current full-year earnings is ($2.01) per share. Wedbush also issued estimates for Stoke Therapeutics' Q2 2025 earnings at ($0.55) EPS, Q3 2025 earnings at ($0.63) EPS, Q4 2025 earnings at ($0.65) EPS, FY2025 earnings at ($2.40) EPS, FY2026 earnings at ($3.06) EPS, FY2027 earnings at ($3.16) EPS, FY2028 earnings at ($2.71) EPS and FY2029 earnings at ($2.03) EPS.

Other equities analysts have also issued reports about the stock. HC Wainwright upped their target price on shares of Stoke Therapeutics from $35.00 to $47.00 and gave the stock a "buy" rating in a research report on Tuesday, February 18th. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Stoke Therapeutics in a report on Tuesday, December 10th. Chardan Capital reiterated a "buy" rating and issued a $24.00 price objective on shares of Stoke Therapeutics in a research report on Wednesday, February 19th. Finally, Needham & Company LLC restated a "buy" rating and set a $22.00 target price on shares of Stoke Therapeutics in a research report on Tuesday, February 18th. One research analyst has rated the stock with a hold rating, eight have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, Stoke Therapeutics presently has a consensus rating of "Buy" and a consensus target price of $23.00.

Remove Ads

Stoke Therapeutics Stock Down 2.9 %

NASDAQ:STOK traded down $0.25 during mid-day trading on Friday, reaching $8.25. 610,955 shares of the company were exchanged, compared to its average volume of 879,368. The stock has a market cap of $436.98 million, a PE ratio of -3.93 and a beta of 0.95. Stoke Therapeutics has a 12 month low of $5.60 and a 12 month high of $17.58. The company has a fifty day moving average of $10.47 and a 200 day moving average of $12.22.

Insider Transactions at Stoke Therapeutics

In related news, CEO Edward M. Md Kaye sold 6,170 shares of the stock in a transaction that occurred on Friday, December 6th. The shares were sold at an average price of $12.78, for a total value of $78,852.60. Following the sale, the chief executive officer now directly owns 68,671 shares in the company, valued at $877,615.38. This trade represents a 8.24 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Barry Ticho sold 2,586 shares of the business's stock in a transaction that occurred on Monday, December 9th. The shares were sold at an average price of $12.99, for a total transaction of $33,592.14. Following the transaction, the insider now owns 44,746 shares of the company's stock, valued at approximately $581,250.54. This represents a 5.46 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 62,849 shares of company stock worth $809,421 in the last three months. Insiders own 11.30% of the company's stock.

Hedge Funds Weigh In On Stoke Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in STOK. KLP Kapitalforvaltning AS bought a new position in Stoke Therapeutics during the fourth quarter worth about $63,000. Teacher Retirement System of Texas bought a new position in shares of Stoke Therapeutics during the 4th quarter valued at about $113,000. China Universal Asset Management Co. Ltd. acquired a new position in shares of Stoke Therapeutics in the 4th quarter valued at approximately $124,000. Tower Research Capital LLC TRC grew its position in shares of Stoke Therapeutics by 70.1% in the 4th quarter. Tower Research Capital LLC TRC now owns 11,930 shares of the company's stock valued at $132,000 after purchasing an additional 4,918 shares during the period. Finally, Invesco Ltd. bought a new stake in Stoke Therapeutics during the 4th quarter worth approximately $133,000.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.